A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema

Diabetic Macular Edema Clinical Trial

— VISION-AF  

Official title:

A Phase IV Interventional Post Approval Trial to Assess the Safety of Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (DME) in Patients in India.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05511038
• Other study ID #: 21974
• Status: Completed
• Phase: Phase 4
• Start date: August 26, 2022
• Est. completion date: April 16, 2024

Study information

• Verified date: April 2024
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Researchers are looking for a better way to treat people who have diabetic macular edema (DME). Diabetic macular edema (DME) is a complication of diabetes. Consistently high blood sugar due to poor glucose control over time can damage small blood vessels in the body, including the eye. Damaged blood vessels in the eye may lead to leakage of the fluid into the central part of the retina at the back of the eye (also called macula) where sharp, straight-ahead vision occurs. Fluid accumulation makes the macula swell and results in reduced vision. If not treated, DME can result in complete loss of central detailed vision. The study treatment intravitreal aflibercept (also called BAY865321) works by blocking VEGFR-1 receptor activity. Intravitreal aflibercept is already approved in over 105 countries for doctors to prescribe to people with DME. In India, aflibercept is approved conditionally for people with DME. The reason for this is that the sponsor was asked to collect more safety data for intravitreal aflibercept in Indian people with DME. The main purpose of this study is to collect more data to learn how safe intravitreal aflibercept is in Indian people with DME. To see how safe intravitreal aflibercept is, the researchers will collect the information/data on the medical problems the participants may have during the study, and which may or may not be related to the study treatment. These medical problems are also known as "adverse events" (AEs). AEs will be categorized according to relatedness, seriousness, discontinuation of therapy, action taken and outcome. The study participants will receive aflibercept as an injection directly into the space in the back of the eye once every 4 weeks in the first 5 months, followed by one injection every 8 weeks for the rest of the study duration. Only one eye per participant to be treated with aflibercept will be considered for the study. Each participant will be in the study for approximately 52 weeks. The treatment duration will be 48 weeks. For each participant 11 visits to the study site are planned. The study team will perform additional safety calls 16 to 36 hours after each visit starting at visit 2. Alternatively, an additional safety visit can be arranged/planned for the day after treatment. During the study, the study team will: - take blood and urine samples - examine the participants' eyes - do physical examinations - examine heart health using ECG - check vital signs - ask the participants questions about how they are feeling and what adverse events they are having. - in- administer the study drug At the end of the study the participants will be switched to commercially available treatment if recommended by the study doctor/if the participant still benefits from the treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: April 16, 2024
• Est. primary completion date: April 16, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Female or male adult participant =18 years of age, with type 1 or 2 diabetes mellitus.
• Participant must have diabetic macular edema (DME) secondary to diabetes mellitus, involving the centre of the macula (defined as the area of the centre subfield of optical coherence tomography (OCT)) in the study eye.
• Decrease in vision, determined to be primarily the result of DME in the study eye.
• Retinal thickness of =300 µm in the study eye, as assessed by OCT.
• Best Corrected Visual Acuity (BCVA) Early Treatment Diabetic Retinopathy Study ( ETDRS) letter score of 73 to 24 (i.e., VA of 20/50 to 20/320) or equivalent in the study eye.
• Participant for whom the decision to initiate treatment with Intravitreal (IVT) aflibercept has been made by the treating Investigator/Physician.
• Willing and able to comply with clinic visits and study-related procedures.
• Provide a signed Informed Consent Form (ICF) prior to any study procedures.

Exclusion Criteria:

• Having any contraindications to the use of IVT aflibercept as listed in the local prescribing information (i.e., ocular or periocular infection, active severe intraocular inflammation, and known hypersensitivity to aflibercept or to any of the excipients).
• History of vitreoretinal surgery and/or scleral buckling in the study eye.
• Ocular conditions with a poorer prognosis in the fellow eye than in the study eye.
• Received previous/ prior treatment as mentioned below:
• Received anti-Vascular Endothelial Growth Factor (VEGF) drugs in the study eye (pegaptanib sodium, bevacizumab, ranibizumab, etc., including aflibercept) within the last 3 months of Day 1.
• Received IVT dexamethasone or triamcinolone in the study eye within the last 3 months of Day 1.
• Received intraocular or periocular corticosteroids in the study eye within the last 4 months of Day 1.
• Had fluocinolone implant in the study eye within the last 3 years of Day 1.
• Had dexamethasone implant in the study eye within the last 6 months of Day 1.
• systemic anti-angiogenic agents within 6 months of Day 1.
• Uncontrolled glaucoma in the study eye (patient who has had filtration surgery in the past, or likely to need filtration surgery in the future).
• Only 1 functional eye even if that eye is otherwise eligible for the study.
• Participated in an investigational study within 30 days prior to screening visit that involved treatment with any drug (excluding vitamins and minerals) or device.
• Pregnant or breast-feeding women.

Related Conditions & MeSH terms

• Diabetic Macular Edema
• Edema
• Macular Edema

Intervention

Drug:
• Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Injection, 2mg (equivalent to 50 µL solution for injection)

Locations

Country	Name	City	State
India	M & J Western Regional Institute of Ophthalmology	Ahmedabad	Gujarat
India	Raghudeep Eye Hospital	Ahmedabad	Gujarat
India	Narayana Nethralaya	Bengaluru	Karnataka
India	Sankara Eye Hospital	Bengaluru	Karnataka
India	Post Graduate Institute of Medical Education and Research	Chandigarh
India	Medical Research Foundation, Sankara Nethralaya	Chennai	Tamil Nadu
India	Lotus Eye Hospital and Institute	Coimbatore	Tamil Nadu
India	L.V. Prasad Eye Institute	Hyderabad	Andhra Pradesh
India	Disha Eye Hospitals	Kolkata	West Bengal
India	Dr. R.P. Centre for Ophthalmic Sciences, AIIMS	New Delhi	Delhi

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of ocular and non-ocular treatment-emergent adverse events (TEAEs)		At week 52
Secondary	Change in best corrected visual acuity (BCVA)	BCVA is assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart or equivalent.	From baseline to week 52
Secondary	Change in central retinal thickness (CRT)	CRT is measured by optical coherence tomography (OCT), Fluorescein Angiography (FA).	From baseline to week 52
Secondary	Proportion of eyes that gain = 5, 10 and 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters		From baseline to week 52
Secondary	Proportion of eyes with a =2 step improvement in the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) score		From baseline to week 52

External Links

•   Click here to find further information and, after study completion, the study results according to Bayer's transparency standards